Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV)


Morphology

  • SS negative-sense RNA virus
  • From the paramyxoviridae family
  • Enveloped nucleocapsid that encodes for 10 viral proteins
  • Matrix is made of M and M2 proteins
  • The viral envelope has two glycoproteins :

G protein:

  • By which virus attaches to cell surface

 F- protein ( Fusion protein:

  • which bring about the fusion between viral and host cell membranes. 
  • It is also responsible for cell to cell fusion, which leads to the characteristic syncytial formation.
Types

RSV can be subtyped into:

  • Type A
  • Type B

 Types account for differences in:

  • The G protein composition
  • The conservation of the F protein in these 2 subtypes

Transmission:  

  • Direct contact with respiratory droplets such as sneezing or coughing
  • Close indirect contact with contaminated fomites such as used tissues
Clinical Manifestations:
  • RSV infection leads to a wide spectrum of respiratory illnesses. 

In infant cause:

  •  pneumonia
  • bronchiolitis
  • tracheobronchitis.
  •  In this age group, illness begins most frequently with rhinorrhea, low-grade fever, often accompanied by a cough and wheezing. 

In adults, the most common symptoms are:

  •  a common cold, with rhinorrhea
  • sore throat
  • cough. 
  • It causes severe pneumonia in elderly. 

Sinusitis, otitis media, and worsening of chronic obstructive and reactive airway disease are also associated with RSV infection.

Diagnosis

For Bronchiolitis:
  • Chest X-ray shows:
  • Hyperinflation 
  • Mul
  • tiple areas of interstitial infiltration

Bud tree Appearance:

  • MC cause of tree in bud (bronchiectasis) appearance is Mycobacterium tuberculosis (endobronchial).
  • Most common specific cause of tree in bud appearance in HSL (bone marrow) transplant patients is:
  • CMV (30-70%) > RSV (18%) > M. tuberculosis (5-6%) > Pneumocystis > Invasive aspergillosis.

Treatment

  • Oxygen: Mainstay of therapy.
  • Aerosolized ribavirin is used in the treatment of bronchiolitis with RSv

Prevention

  • Palivizumab:
  • Humanized monoclonal antibody
  • Directed against an epitope in the A antigen site on the F surface protein of RSV.
  •  Licensed for the prevention of RSV infection in high-risk infants and children.
  • Once-monthly intramuscular injections (15 mg/kg) for 5 months beginning at the start of the RSV season
Exam Question
 

 Morphology

  • SS negative-sense RNA virus
  • The viral envelope has two glycoproteins :

G protein:

  • By which virus attaches to cell surface

 F- protein ( Fusion protein:

  • which bring about the fusion between viral and host cell membranes. 
Types
  • RSV can be subtyped into:
  •  Type A
  • Type B

Clinical Manifestations:

  • RSV infection leads to a wide spectrum of respiratory illnesses. 

In infant cause:

  •  pneumonia
  • bronchiolitis
  • tracheobronchitis.
  •  In this age group, illness begins most frequently with rhinorrhea, low-grade fever, often accompanied by a cough and wheezing. 

In adults, the most common symptoms are:

  •  a common cold, with rhinorrhea
  • sore throat
  • cough. 
  • It causes severe pneumonia in elderly. 

Sinusitis, otitis media, and worsening of chronic obstructive and reactive airway disease are also associated with RSV infection.Diagnosis

For Bronchiolitis:
  • Chest X-ray shows:
  • Hyperinflation 
  • Mu
  • ltiple areas of interstitial infiltration

Bud tree Appearance:

  • MC cause of tree in bud (bronchiectasis) appearance is Mycobacterium tuberculosis (endobronchial).
  • Most common specific cause of tree in bud appearance in HSL (bone marrow) transplant patients is:
  • CMV (30-70%) > RSV (18%) > M. tuberculosis (5-6%) > Pneumocystis > Invasive aspergillosis.

Treatment

  • Oxygen: Mainstay of therapy.
  • Aerosolized ribavirin is used in the treatment of bronchiolitis with RSv

Prevention

  • Palivizumab:
  • Humanized monoclonal antibody
  • Directed against an epitope in the A antigen site on the F surface protein of RSV.
  •  Licensed for the prevention of RSV infection in high-risk infants and children.
  • Once-monthly intramuscular injections (15 mg/kg) for 5 months beginning at the start of the RSV season
Don’t Forget to Solve all the previous Year Question asked on Respiratory Syncytial Virus (RSV)

Leave a Comment

Discover more from New

Subscribe now to keep reading and get access to the full archive.

Continue reading

👨‍⚕️
Chat Support ❌